Get the Stockscreener App
40.86
0.44%
0.1829
Janux Therapeutics Inc stock is traded at $40.86, with a volume of 293.02K.
It is up +0.44% in the last 24 hours and down -29.32% over the past month.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
See More
Previous Close:
$40.68
Open:
$40.44
24h Volume:
293.02K
Relative Volume:
0.27
Market Cap:
$2.39B
Revenue:
$13.05M
Net Income/Loss:
$-60.54M
P/E Ratio:
-35.23
EPS:
-1.16
Net Cash Flow:
$-37.82M
1W Performance:
-6.03%
1M Performance:
-29.32%
6M Performance:
+15.78%
1Y Performance:
+363.79%
1-Day Range:
$39.78
$41.56
1-Week Range:
$39.23
$45.79
52-Week Range:
$7.81
$71.71
Janux Therapeutics Inc Stock (JANX) Company Profile
Name
Janux Therapeutics Inc
Sector
Industry
Phone
(858) 751-4493
Address
10955 VISTA SORRENTO PARKWAY, SAN DIEGO
Compare JANX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
JANX
Janux Therapeutics Inc
|
40.84 | 2.39B | 13.05M | -60.54M | -37.82M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.54 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.76 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
653.03 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.14 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.95 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-24 | Reiterated | BTIG Research | Buy |
| Dec-03-24 | Reiterated | H.C. Wainwright | Buy |
| Nov-22-24 | Initiated | Leerink Partners | Outperform |
| Oct-24-24 | Initiated | UBS | Buy |
| Sep-06-24 | Initiated | Stifel | Buy |
| May-30-24 | Initiated | Scotiabank | Sector Perform |
| Mar-21-24 | Initiated | BTIG Research | Buy |
| Mar-20-24 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-06-23 | Initiated | Wedbush | Outperform |
| Nov-14-22 | Initiated | William Blair | Outperform |
View All
Janux Therapeutics Inc Stock (JANX) Latest News
Janux Therapeutics Inc (JANX): Is It Worth A Small Bite At $40.68? - Stocks Register
The Volatility of Janux Therapeutics Inc’s (JANX) Stock: A -9.18% Ratio for the Week - The News Heater
Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $140,994.86 in Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Shares Up 6.9%Should You Buy? - MarketBeat
Janux Therapeutics Inc (JANX) is looking forward to a strong quarter - SETE News
Janux therapeutics' chief business officer sells shares worth $140,999 - MSN
A Tale of Resilience: Janux Therapeutics Inc Amid Stock Market Turbulence - The InvestChronicle
Insider Sell Alert: Andrew Meyer Sells Shares of Janux Therapeutics Inc (JANX) - GuruFocus.com
Janux Therapeutics (NASDAQ:JANX) Stock Price Down 4.2%Here's Why - MarketBeat
Janux Therapeutics Inc (JANX) stock on the rise: An overview - US Post News
Market Recap: Janux Therapeutics Inc (JANX)’s Negative Momentum, Closing at 42.07 - The Dwinnex
Monitoring Janux Therapeutics Inc (JANX) after recent insider movements - Knox Daily
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Up 19.8% in January - MarketBeat
Nisa Investment Advisors LLC Cuts Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat
Nisa Investment Advisors LLC Trims Stake in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
Core Scientific's chief legal officer sells $410,473 in stock - MSN
Thomas Barnes named CEO of Averna - BioCentury
Advanced Renal Cell Carcinoma Pipeline 2024: Comprehensive - openPR
JPMorgan Chase & Co. Decreases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX) - Defense World
How to Take Advantage of moves in (JANX) - Stock Traders Daily
Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer - BioSpace
Janux Therapeutics, Inc. Promotes Zachariah McIver to Chief Medical Officer -January 24, 2025 at 04:01 pm EST - Marketscreener.com
Janux Therapeutics Names McIver as Chief Medical Officer - MarketWatch
Janux Therapeutics (NASDAQ:JANX) Trading 6.2% HigherHere's What Happened - MarketBeat
Cantor Fitzgerald Forecasts JANX FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts JANX FY2025 Earnings - MarketBeat
Janux Therapeutics surges amid report of takeover interest - MSN
Short Interest in Janux Therapeutics, Inc. (NASDAQ:JANX) Rises By 19.8% - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Trading Down 3.5%Time to Sell? - MarketBeat
The Friday Biotech Perspective #36 - substack.com
Long Term Trading Analysis for (JANX) - Stock Traders Daily
Janux Therapeutics (NASDAQ:JANX) Shares Down 3.5%Time to Sell? - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
JANX Makes Notable Cross Below Critical Moving Average - Nasdaq
BTIG affirms Buy on Janux stock, noting competitive positioning of JANX007 in mCRPC - Investing.com Canada
Janux Therapeutics (NASDAQ:JANX) Given "Outperform" Rating at William Blair - MarketBeat
Cancer data drive significant biopharma stock gains in a volatile 2024 - BioWorld Online
Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) CEO Sells 5,000 Shares of Stock - MarketBeat
Janux Therapeutics CEO David Campbell sells $300,004 in stock By Investing.com - Investing.com Canada
Janux Therapeutics CEO David Campbell sells $300,004 in stock - Investing.com India
Vir Scores In Oncology Pivot With Strong Early T-Cell Engager Results - Citeline News & Insights
Janux Therapeutics (NASDAQ:JANX) Shares Down 6.8%Here's Why - MarketBeat
Janux Therapeutics: mCRPC TAM And Promising JANX007’s Phase 1 Data (NASDAQ:JANX) - Seeking Alpha
Janux Therapeutics (NASDAQ:JANX) Trading Up 7%Still a Buy? - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $731,769.92 in Stock - Defense World
Objective long/short (JANX) Report - Stock Traders Daily
Insider Selling: Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells 13,334 Shares of Stock - MarketBeat
Janux Therapeutics chief business officer sells $731,785 in stock By Investing.com - Investing.com Canada
Viking Therapeutics among potential buyout candidates: Oppenheimer - MSN
Viking stock among buyout targets: Oppenheimer (VKTX:NASDAQ) - Seeking Alpha
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update - MarketBeat
Janux Therapeutics Inc Stock (JANX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Janux Therapeutics Inc Stock (JANX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Meyer Andrew Hollman | Chief Business Officer |
Feb 03 '25 |
Sale |
42.29 |
3,334 |
140,999 |
82,139 |
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):